Suppr超能文献

聚乙二醇聚乙烯己内酰胺介导的具有高溶解度和高稳定性的薯蓣皂苷元无定形固体分散体:研发、表征及口服生物利用度

Soluplus-Mediated Diosgenin Amorphous Solid Dispersion with High Solubility and High Stability: Development, Characterization and Oral Bioavailability.

作者信息

Liu Pei, Zhou Jian-Yu, Chang Jin-Hua, Liu Xi-Gang, Xue He-Fei, Wang Ru-Xing, Li Zhong-Si, Li Chun-Shi, Wang Jian, Liu Cui-Zhe

机构信息

Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.

Hebei Province Key Laboratory of Research and Development for Chinese Medicine, Chengde Medical University, Chengde, Hebei 067000, People's Republic of China.

出版信息

Drug Des Devel Ther. 2020 Jul 27;14:2959-2975. doi: 10.2147/DDDT.S253405. eCollection 2020.

Abstract

BACKGROUND AND PURPOSE

The traditional Chinese medicine, diosgenin (Dio), has attracted increasing attention because it possesses various therapeutic effects, including anti-tumor, anti-infective and anti-allergic properties. However, the commercial application of Dio is limited by its extremely low aqueous solubility and inferior bioavailability in vivo. Soluplus, a novel excipient, has great solubilization and capacity of crystallization inhibition. The purpose of this study was to prepare Soluplus-mediated Dio amorphous solid dispersions (ASDs) to improve its solubility, bioavailability and stability.

METHODS

The crystallization inhibition studies were firstly carried out to select excipients using a solvent shift method. According to solubility and dissolution results, the preparation methods and the ratios of drug to excipient were further optimized. The interaction between Dio and Soluplus was characterized by differential scanning calorimetry (DSC), fourier transform infrared (FT-IR) spectroscopy, scanning electron microscopy (SEM), powder X-ray diffraction (PXRD) and molecular docking. The pharmacokinetic study was conducted to explore the potential of Dio ASDs for oral administration. Furthermore, the long-term stability of Dio ASDs was also investigated.

RESULTS

Soluplus was preliminarily selected from various excipients because of its potential to improve solubility and stability. The optimized ASDs significantly improved the aqueous solubility of Dio due to its amorphization and the molecular interactions between Dio and Soluplus, as evidenced by dissolution test in vitro, DSC, FT-IR spectroscopy, SEM, PXRD and molecular docking technique. Furthermore, pharmacokinetic studies in rats revealed that the bioavailability of Dio from ASDs was improved about 5 times. In addition, Dio ASDs were stable when stored at 40°C and 75% humidity for 6 months.

CONCLUSION

These results indicated that Dio ASDs, with its high solubility, high bioavailability and high stability, would open a promising way in pharmaceutical applications.

摘要

背景与目的

中药薯蓣皂苷元(Dio)因其具有多种治疗作用,包括抗肿瘤、抗感染和抗过敏特性,而受到越来越多的关注。然而,Dio的商业应用受到其极低的水溶性和体内较差的生物利用度的限制。新型辅料Soluplus具有良好的增溶作用和抑制结晶的能力。本研究的目的是制备Soluplus介导的Dio无定形固体分散体(ASD),以提高其溶解度、生物利用度和稳定性。

方法

首先采用溶剂转移法进行抑制结晶研究以筛选辅料。根据溶解度和溶出结果,进一步优化制备方法和药物与辅料的比例。通过差示扫描量热法(DSC)、傅里叶变换红外(FT-IR)光谱、扫描电子显微镜(SEM)、粉末X射线衍射(PXRD)和分子对接对Dio与Soluplus之间的相互作用进行表征。进行药代动力学研究以探索Dio ASD口服给药的潜力。此外,还研究了Dio ASD的长期稳定性。

结果

由于Soluplus具有改善溶解度和稳定性的潜力,因此从多种辅料中初步筛选出该辅料。优化后的ASD由于其无定形化以及Dio与Soluplus之间的分子相互作用,显著提高了Dio的水溶性,体外溶出试验、DSC、FT-IR光谱、SEM、PXRD和分子对接技术均证明了这一点。此外,大鼠药代动力学研究表明,ASD中Dio的生物利用度提高了约5倍。此外,Dio ASD在40°C和75%湿度下储存6个月时是稳定的。

结论

这些结果表明,具有高溶解度、高生物利用度和高稳定性的Dio ASD在药物应用方面将开辟一条有前景的道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a47/7396739/fdcdf311c587/DDDT-14-2959-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验